A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

(2019) Lesley Taylor et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

(2019) James W. Wheless et al.   CNS DRUGS

Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy

(2019) Angela K. Birnbaum et al.   EPILEPSIA

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results

(2018) Jerzy P. Szaflarski et al.   EPILEPSIA

Open-label use of Highly* purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes

(2018) Orrin Devinsky et al.   EPILEPSY & BEHAVIOR

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US

(2018) Tristan T. Sands et al.   CNS DRUGS

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

(2018) Lesley Taylor et al.   CNS DRUGS

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

(2018) Sophie A. Millar et al.   Frontiers in Pharmacology

Cannabinoids in treatment-resistant epilepsy: A review

(2017) Brooke K. O'Connell et al.   EPILEPSY & BEHAVIOR

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

(2016) Orrin Devinsky et al.   LANCET NEUROLOGY

CBD-enriched medical cannabis for intractable pediatric epilepsy

(2016) Michal Tzadok et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

(2014) Orrin Devinsky et al.   EPILEPSIA

Cannabis, cannabidiol, and epilepsy — From receptors to clinical response

(2014) Jerzy P. Szaflarski et al.   EPILEPSY & BEHAVIOR

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8

(2008) L. De Petrocellis et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY